When You Need a Cardiac MRI and What It Can Find

When the angiogram says “clean” and the stress test says “normal” and the symptoms say otherwise, cardiac MRI is often the test that finally agrees with the patient. CMR occupies a specific position in the cardiac workup: it is not a screening tool and it is not a replacement for angiography, but it resolves a set of questions that neither the catheterization lab nor the treadmill can answer. For women presenting with chest pain, elevated troponin, and non-obstructive coronary arteries, those questions are frequently the ones that remain unanswered longest.

The Mechanism

The heart is a muscular organ, and muscle can be injured in ways that do not show up on anatomical pictures of the plumbing. Coronary angiography maps the lumen of the major coronary arteries. It answers the question of whether flow is physically obstructed above 50% in those vessels. What it cannot do is tell you whether the heart muscle supplied by those arteries is scarred, inflamed, stunned, or underperfused at the tissue level. Echocardiography can assess wall motion and structural dimensions, but it does not characterize the myocardium itself with histologic specificity. Exercise ECG measures surface electrical changes under stress, a downstream signal of ischemia several steps removed from the tissue.

Cardiac MRI operates differently. It uses the magnetic properties of hydrogen atoms in tissue, combined with a radiofrequency pulse, to generate images with resolution and tissue contrast that no other modality can replicate noninvasively. For cardiology, two techniques are central.

The first is late gadolinium enhancement (LGE). Gadolinium contrast administered intravenously washes into cardiac tissue, then washes out. In normal myocardium, this washout is complete. In tissue that has been replaced by scar, gadolinium persists, because scar lacks the cellular machinery that clears it. When CMR images are acquired approximately 10 minutes after gadolinium injection, scar tissue appears bright. Normal muscle appears dark. The distribution and transmural depth of enhancement is diagnostically specific. Subendocardial enhancement in a coronary territory indicates ischemic infarction. Midwall or epicardial enhancement indicates myocarditis or other non-ischemic cardiomyopathy. No enhancement in a territory with abnormal wall motion, in the right clinical context, points toward Takotsubo or acute stunning without infarction.

The second technique is stress perfusion imaging. During administration of a vasodilator agent, typically adenosine or regadenoson, gadolinium is infused and images are acquired every heartbeat through the myocardium. Normal microvasculature dilates to four to five times resting flow, so contrast reaches the tissue rapidly and uniformly. Microvascular disease or microvascular obstruction from a prior infarct produces relative underperfusion visible as a perfusion defect: a region that fills more slowly or less completely than surrounding tissue. This maps blood delivery at the level of the capillary, which standard angiography cannot reach.

What the Evidence Shows

The clinical case for cardiac MRI in MINOCA, myocardial infarction with non-obstructive coronary arteries, is well established. Reynolds and colleagues published landmark data demonstrating that CMR performed in MINOCA patients identified a specific etiology in approximately 87% of cases where a cause had not been established at catheterization. Myocarditis accounted for a substantial proportion, ischemic infarct with subendocardial LGE for another, and Takotsubo for a third. Without CMR, most of these patients would have been discharged with documentation of clean arteries and no mechanism identified.

The MR-INFORM trial (Richards et al., The New England Journal of Medicine, 2019) compared CMR perfusion-guided management to invasive fractional flow reserve (FFR)-guided management in patients with stable chest pain. The primary outcome was the rate of major adverse cardiac events at one year. CMR-guided management was non-inferior: 3.9% event rate versus 3.5% for FFR-guided care. Importantly, CMR-guided care resulted in fewer revascularization procedures, suggesting that the test identified who truly needed intervention and who did not. This was a trial of approximately 918 patients, making it large enough to be practice-informing. It validated stress CMR as a clinical decision-making tool, not an academic exercise.

The ISCHEMIA trial (Maron et al., NEJM, 2020) enrolled patients with moderate to severe ischemia on stress testing and randomized them to invasive versus conservative management. A meaningful proportion of the invasively managed group had CMR perfusion imaging as part of their workup. The trial found that invasive management did not reduce the composite of cardiovascular death or MI compared to optimal medical therapy in stable patients, which reframed the role of imaging: it matters more for identifying mechanism and guiding treatment than for triggering revascularization in stable disease.

For Takotsubo specifically, CMR provides information that no other test can. The Japan Registry data on Takotsubo and several European series, including work from Templin and colleagues published in NEJM in 2015, describe the characteristic apical ballooning pattern and document that LGE is absent in uncomplicated Takotsubo, distinguishing it from anterior infarction. CMR also quantifies functional recovery over time, which matters for decisions about neurohormonal therapy.

For myocarditis, the Lake Louise Criteria, updated in 2018 by Ferreira and colleagues in JACC Cardiovascular Imaging, provide a validated framework for CMR diagnosis. The updated criteria incorporate T1 and T2 mapping sequences, which detect tissue water content and extracellular volume changes that precede scar formation. Sensitivity for acute myocarditis with these updated criteria exceeds 88% in studies from the Heidelberg and Vienna CMR groups.

What CMR Adds That Other Tests Cannot

Echocardiography evaluates structure and function well. Angiography defines coronary anatomy. Exercise ECG detects surface electrical changes during stress. None of these characterizes the myocardium itself at a tissue level. Cardiac MRI does.

Using late gadolinium enhancement, CMR identifies where contrast accumulates in the heart muscle after it washes out of normal tissue. The pattern of enhancement is diagnostically specific: ischemic infarcts enhance in a subendocardial or transmural distribution following a coronary territory. Myocarditis shows patchy or epicardial enhancement. Hypertrophic cardiomyopathy has a characteristic mid-wall pattern. These patterns are distinct, and distinguishing them changes treatment.

Beyond tissue characterization, CMR with pharmacological stress and gadolinium perfusion imaging can detect reduced myocardial blood flow at the tissue level. A vasodilator agent, adenosine or regadenoson, dilates normal coronary microvasculature; diseased or dysfunctional microvasculature fails to dilate appropriately. CMR perfusion imaging captures this as a difference in contrast delivery across the myocardium during stress. This makes stress perfusion CMR particularly useful in suspected microvascular coronary dysfunction, where the large coronary arteries are unobstructed but the resistance vessels fail to meet increased myocardial oxygen demand.

CMR in MINOCA

Myocardial infarction with non-obstructive coronary arteries is over-represented in women. The angiogram is clean, the troponin is elevated, and the working diagnosis is uncertain. CMR is the recommended next step. In the MINOCA population, CMR identifies the mechanism in a substantial proportion of cases.

That distinction is not academic. Myocarditis is managed differently from ischemic infarct. Takotsubo requires different follow-up. A small ischemic scar from plaque erosion or distal embolism suggests a different secondary prevention approach than clean coronary disease. CMR makes these distinctions. The angiogram does not.

The European Society of Cardiology MINOCA working group, in a position paper by Agewall and colleagues published in European Heart Journal (2017), formally recommended CMR as a central component of the MINOCA evaluation. The 2021 ESC guidelines on acute coronary syndromes further solidified this recommendation. These are not aspirational suggestions; CMR in MINOCA is now standard-of-care guidance in major cardiology society recommendations.

CMR in Takotsubo Cardiomyopathy

Takotsubo cardiomyopathy, the transient left ventricular dysfunction triggered by physical or emotional stress, occurs predominantly in postmenopausal women. At presentation, it can be indistinguishable from an anterior STEMI. CMR during the subacute phase shows the characteristic apical ballooning and basal sparing of wall motion, combined with absent late gadolinium enhancement, which distinguishes Takotsubo from ischemic infarct and from myocarditis.

That distinction at presentation or shortly after guides anticoagulation decisions, beta-blocker use, and expectations about recovery. The Templin registry data established that Takotsubo is not uniformly benign: in-hospital mortality was 1.8%, and complications including cardiogenic shock and ventricular arrhythmia occurred in a meaningful minority. Knowing the diagnosis early matters for managing those risks. CMR in the first one to four weeks after an event provides the tissue-level confirmation that the bedside presentation cannot.

When CMR Is the Appropriate Next Step

CMR is not a first-line screening test. It is the right tool when specific questions need tissue-level answers. Appropriate indications include: unexplained troponin elevation with non-obstructive coronaries (MINOCA workup); suspected myocarditis with chest pain, ECG changes, and preserved or mildly reduced ejection fraction; Takotsubo characterization and distinction from ischemic infarction; ongoing ischemic symptoms with non-diagnostic standard stress testing; pre-operative planning when ventricular function and scar burden matter; and evaluation of cardiomyopathy etiology when the diagnosis would change treatment.

What CMR does not replace: invasive angiography for defining stenosis severity and guiding revascularization; coronary CTA for anatomical coronary artery imaging; and transthoracic echocardiography for rapid, repeated functional assessment. These are complementary modalities. The clinical question determines which is needed.

For women in the “The Unseen Coronary” category, the relevant indications are MINOCA workup and stress perfusion assessment for suspected microvascular dysfunction. These are exactly the scenarios where standard tests have already delivered a normal result while symptoms persist.

Practical constraints include scanner availability, cost, and the time required for a complete protocol. A standard cardiac MRI for tissue characterization runs 45 to 75 minutes. Stress perfusion adds pharmacologic preparation time. For the right clinical question in the right patient, those constraints are worth navigating.

T1 and T2 Parametric Mapping: The CMR Sequences That Detect What LGE Cannot

Late gadolinium enhancement identifies focal, irreversible scar — tissue where myocytes have been replaced by collagen and gadolinium is retained because the normal cellular clearance mechanisms are absent. It is diagnostically powerful for identifying prior infarction, regional myocarditis, and infiltrative disease with focal distribution. What it cannot detect is diffuse interstitial fibrosis: the process by which collagen is deposited between myocytes throughout the myocardium without killing them, expanding the extracellular space without creating the focal bright region that LGE imaging requires.

Diffuse fibrosis is the substrate underlying a substantial proportion of heart failure with preserved ejection fraction (HFpEF), a condition that is approximately twice as common in women as in men and that carries substantial morbidity and mortality while being poorly served by current therapies. In HFpEF, the myocardium stiffens, diastolic filling is impaired, and exertional dyspnea develops in the presence of normal LV systolic function — and normal LGE. The standard CMR protocol can miss this entirely.

T1 mapping addresses this. By measuring the longitudinal relaxation time of myocardial tissue before gadolinium (native T1) and after gadolinium, combined with a blood pool T1 measurement, T1 mapping enables calculation of the extracellular volume fraction (ECV) — the proportion of myocardial volume occupied by extracellular matrix rather than cardiomyocytes. Normal ECV is approximately 25 to 27 percent. Values above 30 percent indicate pathological diffuse fibrosis. Moon and colleagues, reporting in the Journal of the American Heart Association in 2013, demonstrated that ECV quantified by T1 mapping was independently associated with all-cause mortality in patients with systemic cardiac disease, with each 1% increase in ECV carrying incrementally higher risk. In women with hypertensive heart disease or diabetic cardiomyopathy, elevated ECV by T1 mapping can be present and prognostically relevant even when the LGE image is clean.

T2 mapping detects myocardial edema by quantifying the transverse relaxation time, which lengthens when tissue water content is elevated. Acute myocarditis, acute infarction, and inflammatory cardiomyopathy all produce T2 elevation in affected regions. The 2018 update to the Lake Louise Criteria by Ferreira and colleagues incorporated both T1 and T2 mapping as formal diagnostic components, increasing diagnostic sensitivity for acute myocarditis to above 88 percent in validation cohorts. In a woman presenting with an acute chest pain syndrome and clean coronary arteries, the combination of elevated native T1 and regional T2 elevation on CMR is now a validated diagnostic pathway for myocarditis that does not require endomyocardial biopsy.

What to Do This Week

1. If you have had a troponin elevation, were told your coronary arteries were clean, and do not have a clear diagnosis explaining the event, ask your cardiologist specifically whether cardiac MRI has been ordered or considered as part of your MINOCA workup. The AHA and ESC both recommend it in this scenario.

2. If your stress test was normal but your symptoms are ongoing, ask whether a stress perfusion CMR would provide more specific information about microvascular blood flow. The standard stress test and stress CMR answer different questions; a normal ECG stress test does not make stress CMR redundant.

3. If you have been diagnosed with Takotsubo or suspected myocarditis, ask whether CMR tissue characterization is part of the planned workup. The distinction between these two diagnoses and between either and ischemic infarction changes your follow-up plan and your treatment.

4. If CMR has not been offered and you believe you fit the indication, ask for a referral to a center with cardiac MRI capability. Many community hospitals do not have CMR programs; academic and tertiary centers routinely do.

5. Before any CMR appointment, confirm your kidney function has been checked (a GFR is typically required before gadolinium administration) and disclose all implanted devices. Most modern pacemakers and defibrillators are MRI-conditional, but this must be verified in advance.

Cardiac MRI is a high-resolution answer to questions that surface-level tests leave open. In a condition defined by coronary disease that goes unseen on standard testing, it is the test most capable of making the invisible visible, particularly in MINOCA, microvascular disease, and the conditions that mimic infarction without obstructing an artery. A normal angiogram is the beginning of the MINOCA workup. Cardiac MRI is often where that workup ends with an answer.